Piersson A D, Gorleku P N
Department of Imaging Technology & Sonography, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Central Region, Ghana; Corston Health System Ltd, P.O. Box GP 4560, Accra, Ghana.
Department of Imaging Technology & Sonography, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Central Region, Ghana.
Radiography (Lond). 2018 Aug;24(3):e51-e55. doi: 10.1016/j.radi.2017.12.009. Epub 2017 Dec 30.
The aim of the survey was to identify current practice of the use of gadolinium-based contrast agents (GBCAs) in the wake of recent reports on gadolinium deposition in the brain following repeated administration of GBCAs.
A total of 13 facilities in Ghana with magnetic resonance imaging (MRI) departments were contacted via email with a two-page questionnaire.
A response rate of 69.2% (n = 9) was achieved. Gadodiamide (Omniscan) was the most commonly used GBCA. Slightly more than half of respondents were aware of residual deposition of GBCAs in the brain. Majority of the respondents were aware of GBCA deposition in individuals with abnormal renal function, but not aware of its deposition in those with normal renal function. A great majority of the respondents do not record the type and dose of GBCA after each intravenous administration, and such information is not provided in MRI reports. More than half of the respondents do not check eGFR prior to the administration of GBCA even when a high-risk agent is used.
Gadodiamide (Omniscan) a high-risk agent remains the most commonly used GBCA in Ghana. Awareness of current findings of GBCA deposition in the brain following repeated doses are not encouraging as revealed in this study. The need to adopt international standard guidelines into practice cannot be overemphasized in order to reduce the potential long-term effect of this deposition.
此次调查的目的是，鉴于近期有报告称重复使用钆基造影剂（GBCA）后钆会在脑部沉积，确定目前GBCA的使用情况。
通过电子邮件向加纳13家设有磁共振成像（MRI）科室的机构发送了一份两页的调查问卷。
回复率为69.2%（n = 9）。钆双胺（欧乃影）是最常用的GBCA。略超过半数的受访者知晓GBCA在脑部的残留沉积情况。大多数受访者知晓肾功能异常者体内会出现GBCA沉积，但不知晓肾功能正常者体内也会出现这种沉积。绝大多数受访者在每次静脉注射GBCA后不记录其类型和剂量，MRI报告中也未提供此类信息。超过半数的受访者即使使用高风险造影剂，在注射GBCA前也不检查估算肾小球滤过率（eGFR）。
高风险造影剂钆双胺（欧乃影）仍是加纳最常用的GBCA。正如本研究所示，对重复给药后GBCA在脑部沉积的当前研究结果的认知情况不容乐观。为减少这种沉积的潜在长期影响，将国际标准指南应用于实际操作的必要性再怎么强调也不为过。
